Lilly Asia Ventures and existing investor Taiho Ventures both contributed to a round for immunotherapy developer Harpoon Therapeutics following a $45m series B last year.
US-based immunotherapy developer Harpoon Therapeutics completed a $70m series C round on Friday that included Lilly Asia Ventures and Taiho Ventures, corporate venturing subsidiaries of pharmaceutical firms Eli Lilly and Taiho.
The round was led by healthcare investment firm OrbiMed and also featured Cormorant Asset Management, Oncology Impact Fund, Arix Bioscience, Ridgeback Capital Investments, NS Investment, MPM Capital and New Leaf Venture Partners.
Harpoon is working on T cell engagers based on its tri-specific T cell activating construct (Tritac) platform…
